You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMycophenolate mofetil
Accession NumberDB00688  (APRD01602)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionMycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), an immunosuppressive agent, inosine monophosphate dehydrogenase (IMPDH) inhibitor.
Structure
Thumb
Synonyms
2-Morpholinoethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate
Cellcept
MMF
Mycophenolic acid morpholinoethyl ester
RS 61443
External Identifiers
  • 168396
  • RS 61443
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Accel-mycophenolate Mofetil Capsulescapsule250 mgoralAccel Pharma IncNot applicableNot applicableCanada
Accel-mycophenolate Mofetil Tabletstablet500 mgoralAccel Pharma IncNot applicableNot applicableCanada
Ach-mycophenolatecapsule250 mgoralAccord Healthcare Inc2012-05-01Not applicableCanada
Cellceptcapsule250 mg/1oralCardinal Health1995-05-03Not applicableUs
Cellceptcapsule250 mg/1oralGenentech, Inc.1995-05-03Not applicableUs
CellceptCapsule, hard250 mgOral useRoche Registration Ltd.1996-02-14Not applicableEu
Cellceptpowder for suspension200 mgoralHoffmann La Roche Limited2002-08-27Not applicableCanada
Cellceptcapsule250 mg/1oralRebel Distributors Corp1995-05-03Not applicableUs
Cellceptcapsule250 mgoralHoffmann La Roche Limited1995-12-31Not applicableCanada
Cellcepttablet, film coated500 mg/1oralGenentech, Inc.1997-06-19Not applicableUs
CellceptPowder for concentrate for solution for infusion500 mgIntravenous useRoche Registration Ltd.1996-02-14Not applicableEu
Cellceptcapsule250 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-29Not applicableUs
Cellcepttablet500 mgoralHoffmann La Roche Limited1998-11-11Not applicableCanada
Cellceptpowder, for suspension200 mg/mLoralGenentech, Inc.1998-10-01Not applicableUs
CellceptTablet500 mgOral useRoche Registration Ltd.1996-02-14Not applicableEu
Cellcepttablet, film coated500 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC1997-06-19Not applicableUs
Cellceptinjection, powder, lyophilized, for solution500 mg/20mLintravenousGenentech, Inc.1998-08-12Not applicableUs
CellceptTablet500 mgOral useRoche Registration Ltd.1996-02-14Not applicableEu
CellceptCapsule, hard250 mgOral useRoche Registration Ltd.1996-02-14Not applicableEu
Cellcept I.V.powder for solution500 mgintravenousHoffmann La Roche Limited1999-12-20Not applicableCanada
Co Mycophenolatetablet500 mgoralCobalt Pharmaceuticals Company2012-02-14Not applicableCanada
Jamp-mycophenolatetablet500 mgoralJamp Pharma Corporation2012-03-23Not applicableCanada
Jamp-mycophenolate Capsulescapsule250 mgoralJamp Pharma Corporation2012-06-13Not applicableCanada
Mycophenolate Mofetil for Injection, USPpowder for solution500 mgintravenousAccord Healthcare IncNot applicableNot applicableCanada
Mycophenolate Mofetil Tabletstablet500 mgoralAccord Healthcare Inc2012-02-16Not applicableCanada
Mylan-mycophenolatetablet500 mgoralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Mylan-mycophenolatecapsule250 mgoralMylan Pharmaceuticals Ulc2011-11-30Not applicableCanada
Novo-mycophenolatetablet500 mgoralTeva Canada Limited2011-11-30Not applicableCanada
Novo-mycophenolatecapsule250 mgoralTeva Canada Limited2011-11-30Not applicableCanada
Ran-mycophenolatetablet500 mgoralRanbaxy Pharmaceuticals Canada Inc.Not applicableNot applicableCanada
Sandoz Mycophenolate Mofetiltablet500 mgoralSandoz Canada Incorporated2011-11-30Not applicableCanada
Sandoz Mycophenolate Mofetilcapsule250 mgoralSandoz Canada Incorporated2011-11-30Not applicableCanada
Van-mycophenolatecapsule250 mgoralVanc Pharmaceuticals Inc2015-07-22Not applicableCanada
Van-mycophenolatetablet500 mgoralVanc Pharmaceuticals Inc2015-07-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mycophenolatecapsule250 mgoralApotex Inc2011-12-01Not applicableCanada
Apo-mycophenolatetablet500 mgoralApotex Inc2011-12-01Not applicableCanada
Mycophenolate Mofetiltablet500 mg/1oralSandoz Inc2008-10-15Not applicableUs
Mycophenolate Mofetiltablet, coated500 mg/1oralAmerican Health Packaging2012-07-022015-12-31Us
Mycophenolate Mofetiltablet, film coated500 mg/1oralStrides Arcolab Limited2010-11-06Not applicableUs
Mycophenolate Mofetiltablet, film coated500 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.2013-08-01Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralRoxane Laboratories, Inc2008-07-29Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Mycophenolate Mofetiltablet, film coated500 mg/1oralAscend Laboratories, LLC2011-11-28Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralMylan Institutional Inc.2009-06-01Not applicableUs
Mycophenolate Mofetiltablet, film coated500 mg/1oralGolden State Medical Supply, Inc.2015-01-06Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralMylan Pharmaceuticals Inc.2009-05-04Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralAvera Mc Kennan Hospital2015-03-01Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralStrides Arcolab Limited2010-11-06Not applicableUs
Mycophenolate Mofetiltablet500 mg/1oralAccord Healthcare Inc.2009-05-04Not applicableUs
Mycophenolate Mofetiltablet, film coated500 mg/1oralGreenstone LLC2010-06-11Not applicableUs
Mycophenolate Mofetiltablet500 mg/1oralRoxane Laboratories, Inc2008-07-29Not applicableUs
Mycophenolate Mofetiltablet500 mg/1oralAmerican Health Packaging2014-12-15Not applicableUs
Mycophenolate Mofetilpowder, for suspension200 mg/mLoralAscend Laboratories, LLC2014-11-17Not applicableUs
Mycophenolate Mofetiltablet500 mg/1oralCardinal Health2011-10-25Not applicableUs
Mycophenolate Mofetiltablet, coated500 mg/1oralApotex Corp2009-05-04Not applicableUs
Mycophenolate Mofetiltablet, film coated500 mg/1oralMylan Pharmaceuticals Inc.2009-05-04Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralQualitest Pharmaceuticals2010-03-162015-12-29Us
Mycophenolate Mofetilcapsule250 mg/1oralCadila Healthcare Limited2009-05-04Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralAccord Healthcare Inc.2009-05-04Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralGreenstone LLC2010-06-11Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralTeva Pharmaceuticals USA Inc2009-05-06Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-05-04Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralAscend Laboratories, LLC2010-01-01Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralCardinal Health2011-10-25Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralApotex Corp2009-05-04Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralSandoz Inc2008-10-15Not applicableUs
Mycophenolate Mofetiltablet500 mg/1oralQualitest Pharmaceuticals2010-07-192015-12-29Us
Mycophenolate Mofetiltablet, film coated500 mg/1oralCadila Healthcare Limited2009-05-04Not applicableUs
Mycophenolate Mofetiltablet, film coated500 mg/1oralMylan Institutional Inc.2009-06-01Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralGolden State Medical Supply, Inc.2015-01-06Not applicableUs
Mycophenolate Mofetiltablet, film coated500 mg/1oralTeva Pharmaceuticals USA Inc2009-05-05Not applicableUs
Mycophenolate Mofetiltablet, film coated500 mg/1oralZydus Pharmaceuticals (USA) Inc.2009-05-04Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralAmerican Health Packaging2012-07-02Not applicableUs
Mycophenolate Mofetilcapsule250 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.2013-08-01Not applicableUs
Mycophenolate Mofetil TevaCapsule, hard250 mgOral useTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaCapsule, hard250 mgOral useTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaFilm-coated tablet500 mgOral useTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaFilm-coated tablet500 mgOral useTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaCapsule, hard250 mgOral useTeva Pharma B.V.2008-02-21Not applicableEu
Mycophenolate Mofetil TevaFilm-coated tablet500 mgOral useTeva Pharma B.V.2008-02-21Not applicableEu
MyfenaxFilm-coated tablet500 mgOral useTeva B.V.2008-02-21Not applicableEu
MyfenaxCapsule, hard250 mgOral useTeva B.V.2008-02-21Not applicableEu
MyfenaxFilm-coated tablet500 mgOral useTeva B.V.2008-02-21Not applicableEu
MyfenaxCapsule, hard250 mgOral useTeva B.V.2008-02-21Not applicableEu
MyfenaxCapsule, hard250 mgOral useTeva B.V.2008-02-21Not applicableEu
MyfenaxFilm-coated tablet500 mgOral useTeva B.V.2008-02-21Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CellCept Oral Suspension Genentech USA, Inc.
CellCept IntravenousGenentech USA, Inc.
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Mycophenolate mofetil hydrochloride
ThumbNot applicableDBSALT001477
Categories
UNII9242ECW6R0
CAS number128794-94-5
WeightAverage: 433.4947
Monoisotopic: 433.210052351
Chemical FormulaC23H31NO7
InChI KeyInChIKey=RTGDFNSFWBGLEC-SYZQJQIISA-N
InChI
InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+
IUPAC Name
2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate
SMILES
COC1=C(C\C=C(/C)CCC(=O)OCCN2CCOCC2)C(O)=C2C(=O)OCC2=C1C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phthalides. These are compounds containing a 3-hydrocarbylidene-2-benzofuran-1(3H)-one moiety,.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassIsobenzofurans
Sub ClassIsobenzofuranones
Direct ParentPhthalides
Alternative Parents
Substituents
  • Phthalide
  • Methoxyphenol
  • Anisole
  • Fatty acid ester
  • Alkyl aryl ether
  • Fatty acyl
  • Benzenoid
  • Oxazinane
  • Morpholine
  • Dicarboxylic acid or derivatives
  • Vinylogous acid
  • Tertiary aliphatic amine
  • Tertiary amine
  • Lactone
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. Mycophenolate mofetil should be used concomitantly with cyclosporine and corticosteroids.
PharmacodynamicsMycophenolate mofetil is a prodrug of mycophenolic acid (MPA), an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.
Mechanism of actionMycophenolate mofetil is hydrolyzed to form mycophenolic acid (MPA), which is the active metabolite. MPA is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, MPA has potent cytostatic effects on lymphocytes. MPA inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of MPA on lymphocytes. MPA also suppresses antibody formation by B-lymphocytes. MPA prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection. Mycophenolate mofetil did not inhibit early events in the activation of human peripheral blood mononuclear cells, such as the production of interleukin-1 (IL-1) and interleukin-2 (IL-2), but did block the coupling of these events to DNA synthesis and proliferation.
Related Articles
AbsorptionRapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. The absolute bioavailability of the delayed release tablet in stable renal transplant patients on cyclosporin is 72%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.
Volume of distribution
  • 3.6 ±1.5 L/kg [intravenous, healthy subjects, MPA]
  • 4 ±1.2 L/kg [oral administration, healthy subjects, MPA]
Protein bindingMPA (the active metabolite), at clinically relevant concentrations, is over 98% bound to plasma albumin. The phenolic glucuronide of MPA, mycophenolic acid glucuronide (MPAG) has 82% protein bound.
Metabolism

Following oral and intravenous dosing, mycophenolate mofetil undergoes complete metabolism to MPA, the active metabolite. Metabolism to MPA occurs presystemically after oral dosing. MPA is metabolized principally by glucuronyl transferase to form the phenolic glucuronide of MPA (MPAG) which is not pharmacologically active. In vivo, MPAG is converted to MPA via enterohepatic recirculation. The following metabolites of the 2-hydroxyethyl-morpholino moiety are also recovered in the urine following oral administration of mycophenolate mofetil to healthy subjects: N-(2-carboxymethyl)-morpholine, N-(2-hydroxyethyl)-morpholine, and the N-oxide of N-(2-hydroxyethyl)-morpholine. Cytochrome P450 isozymes, CYP3A4/5 and to a lesser extent by CYP2C8, is responsible for the biotransformation of MPA to 6-O-desmethyl-mycophenolic acid.

SubstrateEnzymesProduct
Mycophenolate mofetil
Not Available
Mycophenolic acid (MPA)Details
Mycophenolate mofetil
Not Available
Mycophenolic acid glucuronideDetails
Mycophenolate mofetil
Not Available
N-(2-carboxymethyl)-morpholineDetails
Mycophenolate mofetil
Not Available
N-(2-hydroxyethyl)-morpholineDetails
Mycophenolate mofetil
Not Available
N-(2-hydroxyethyl)-morpholine N-oxideDetails
Route of eliminationNegligible amount of drug is excreted as MPA (< 1% of dose) in the urine. When orally administered, mycophenolate mofetil was completely recovered with 93% of the dose found in the urine and 6% found in feces. 87% of the administered dose is excreted in the urine as MPAG.
Half lifeThe mean elimination half-life for mycophenolic acid (the active metabolite) ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.
Clearance
  • 193 mL/min [plasma clearance, MPA, oral administration]
  • 177 mL/min [plasma clearance, MPA, IV administration]
  • 15.5 mL/min [renal clearance, MPAG, delayed-release tablet]
ToxicityOral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Mycophenolic Acid Metabolism PathwayDrug metabolismSMP00652
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8938
Blood Brain Barrier+0.8594
Caco-2 permeable+0.5904
P-glycoprotein substrateSubstrate0.8908
P-glycoprotein inhibitor IInhibitor0.8381
P-glycoprotein inhibitor IIInhibitor0.8061
Renal organic cation transporterInhibitor0.5379
CYP450 2C9 substrateNon-substrate0.8528
CYP450 2D6 substrateNon-substrate0.602
CYP450 3A4 substrateSubstrate0.7646
CYP450 1A2 substrateNon-inhibitor0.6878
CYP450 2C9 inhibitorNon-inhibitor0.9155
CYP450 2D6 inhibitorNon-inhibitor0.7684
CYP450 2C19 inhibitorNon-inhibitor0.9122
CYP450 3A4 inhibitorNon-inhibitor0.8316
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8664
Ames testNon AMES toxic0.6484
CarcinogenicityNon-carcinogens0.953
BiodegradationNot ready biodegradable0.658
Rat acute toxicity3.0412 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.771
hERG inhibition (predictor II)Non-inhibitor0.7653
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Roche palo alto llc
  • Accord healthcare inc usa
  • Apotex corp
  • Endo pharmaceuticals inc
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Strides arcolab ltd
  • Teva pharmaceuticals usa
  • Zydus pharmaceuticals usa inc
  • Accord healthcare inc
  • Apotex inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral250 mg/1
Capsuleoral250 mg
Capsule, hardOral use250 mg
Injection, powder, lyophilized, for solutionintravenous500 mg/20mL
Powder for concentrate for solution for infusionIntravenous use500 mg
Powder for suspensionoral200 mg
Powder, for suspensionoral200 mg/mL
Tabletoral500 mg
TabletOral use500 mg
Tablet, film coatedoral500 mg/1
Powder for solutionintravenous500 mg
Tabletoral500 mg/1
Tablet, coatedoral500 mg/1
Film-coated tabletOral use500 mg
Prices
Unit descriptionCostUnit
CellCept 200 mg/ml Suspension 175ml Bottle875.84USD bottle
Cellcept 500 mg vial65.03USD vial
Cellcept 500 mg tablet10.43USD tablet
Mycophenolate Mofetil 500 mg tablet8.25USD tablet
Mycophenolate 500 mg tablet7.93USD tablet
CellCept 250 mg capsule5.21USD capsule
Mycophenolate Mofetil 250 mg capsule4.13USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1333285 No1994-11-292011-11-29Canada
CA2172506 No2007-07-172014-09-27Canada
US5543408 No1993-09-152013-09-15Us
US5688529 No1994-11-182014-11-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly soluble (43 mg/mL at pH 7.4)Not Available
logP2.5Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.095 mg/mLALOGPS
logP2.17ALOGPS
logP3.47ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)9.76ChemAxon
pKa (Strongest Basic)6.19ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area94.53 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity117.1 m3·mol-1ChemAxon
Polarizability45.55 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Roger C. Fu, De-Mei Leung, Jeffrey S. Fleitman, Michele C. Rizzolio, Andrew R. Miksztal, “Process for preparing pharmaceutical compositions containing crystalline anhydrous mycophenolate mofetil salts.” U.S. Patent US5545637, issued November, 1988.

US5545637
General References
  1. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. [PubMed:15899149 ]
  2. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
External Links
ATC CodesNot Available
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (200 KB)
MSDSDownload (82.3 KB)
Interactions
Drug Interactions
Drug
AbciximabMycophenolate mofetil may increase the anticoagulant activities of Abciximab.
AbirateroneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Abiraterone.
AcebutololMycophenolate mofetil may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Aceclofenac.
AcenocoumarolMycophenolate mofetil may increase the anticoagulant activities of Acenocoumarol.
AcetaminophenThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Acetaminophen.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Acetylsalicylic acid.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolate mofetil.
AfatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Alectinib.
Alendronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Alendronic acid.
AlfentanilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Alfentanil.
AliskirenMycophenolate mofetil may decrease the antihypertensive activities of Aliskiren.
AlprenololMycophenolate mofetil may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mycophenolate mofetil.
AmantadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amantadine.
AmikacinMycophenolate mofetil may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideMycophenolate mofetil may decrease the antihypertensive activities of Amiloride.
Aminohippuric acidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amlodipine.
AmprenavirThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Amsacrine.
AncrodMycophenolate mofetil may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Antipyrine.
Antithrombin III humanMycophenolate mofetil may increase the anticoagulant activities of Antithrombin III human.
ApixabanMycophenolate mofetil may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Apremilast.
AprepitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Aprepitant.
ArdeparinMycophenolate mofetil may increase the anticoagulant activities of Ardeparin.
ArgatrobanMycophenolate mofetil may increase the anticoagulant activities of Argatroban.
ArotinololMycophenolate mofetil may decrease the antihypertensive activities of Arotinolol.
AstemizoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atazanavir.
AtenololMycophenolate mofetil may decrease the antihypertensive activities of Atenolol.
AtenololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Mycophenolate mofetil can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Atorvastatin.
AzapropazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolate mofetil.
AzithromycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Azithromycin.
BalsalazideMycophenolate mofetil may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Mycophenolate mofetil.
BecaplerminMycophenolate mofetil may increase the anticoagulant activities of Becaplermin.
BefunololMycophenolate mofetil may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Mycophenolate mofetil.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.
BenoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Benoxaprofen.
BenzocaineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Benzocaine.
BepridilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bepridil.
BetaxololMycophenolate mofetil may decrease the antihypertensive activities of Betaxolol.
BevantololMycophenolate mofetil may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolate mofetil.
BiperidenThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Biperiden.
BisoprololMycophenolate mofetil may decrease the antihypertensive activities of Bisoprolol.
BivalirudinMycophenolate mofetil may increase the anticoagulant activities of Bivalirudin.
BoceprevirThe metabolism of Mycophenolate mofetil can be decreased when combined with Boceprevir.
BopindololMycophenolate mofetil may decrease the antihypertensive activities of Bopindolol.
BortezomibThe metabolism of Mycophenolate mofetil can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bosutinib.
BromfenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Bromfenac.
BromocriptineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Bromocriptine.
BufuralolMycophenolate mofetil may decrease the antihypertensive activities of Bufuralol.
BumetanideMycophenolate mofetil may decrease the diuretic activities of Bumetanide.
BupranololMycophenolate mofetil may decrease the antihypertensive activities of Bupranolol.
BuprenorphineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Canagliflozin.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolate mofetil.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Mycophenolate mofetil.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Mycophenolate mofetil.
CarbamazepineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Carbamazepine.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolate mofetil.
CarprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Carprofen.
CarteololMycophenolate mofetil may decrease the antihypertensive activities of Carteolol.
CarvedilolMycophenolate mofetil may decrease the antihypertensive activities of Carvedilol.
CarvedilolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Caspofungin.
CastanospermineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Mycophenolate mofetil.
CeliprololMycophenolate mofetil may decrease the antihypertensive activities of Celiprolol.
CeritinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ceritinib.
CertoparinMycophenolate mofetil may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolate mofetil.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolate mofetil.
ChlorpromazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Chlorprothixene.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolate mofetil.
CholesterolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cholesterol.
CholestyramineCholestyramine can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Cholic Acid.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Mycophenolate mofetil.
CimetidineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Citalopram.
Citric AcidMycophenolate mofetil may increase the anticoagulant activities of Citric Acid.
ClarithromycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Mycophenolate mofetil can be decreased when combined with Clemastine.
ClodronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clodronate.
ClofazimineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Clomipramine.
ClonixinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Clonixin.
ClopidogrelThe metabolism of Mycophenolate mofetil can be decreased when combined with Clopidogrel.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mycophenolate mofetil.
ClotrimazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColforsinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Crizotinib.
CyclophosphamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Cyclophosphamide.
CyclosporineMycophenolate mofetil may increase the nephrotoxic activities of Cyclosporine.
CyclosporineThe metabolism of Mycophenolate mofetil can be decreased when combined with Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with D-Limonene.
Dabigatran etexilateMycophenolate mofetil may increase the anticoagulant activities of Dabigatran etexilate.
DabrafenibThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dactinomycin.
DalteparinMycophenolate mofetil may increase the anticoagulant activities of Dalteparin.
DanaparoidMycophenolate mofetil may increase the anticoagulant activities of Danaparoid.
DarunavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dasatinib.
DaunorubicinMycophenolate mofetil may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DaunorubicinThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Daunorubicin.
DeferasiroxThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Deferasirox.
DelavirdineThe metabolism of Mycophenolate mofetil can be decreased when combined with Delavirdine.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolate mofetil.
DesipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desipramine.
DesirudinMycophenolate mofetil may increase the anticoagulant activities of Desirudin.
DesloratadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Desmopressin.
DexamethasoneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Dexamethasone.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mycophenolate mofetil.
DextranMycophenolate mofetil may increase the anticoagulant activities of Dextran.
Dextran 40Mycophenolate mofetil may increase the anticoagulant activities of Dextran 40.
Dextran 70Mycophenolate mofetil may increase the anticoagulant activities of Dextran 70.
Dextran 75Mycophenolate mofetil may increase the anticoagulant activities of Dextran 75.
DextromethorphanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dextromethorphan.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Mycophenolate mofetil.
DicoumarolMycophenolate mofetil may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Diflunisal.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mycophenolate mofetil.
DigoxinThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Digoxin.
DihydroergotamineThe metabolism of Mycophenolate mofetil can be decreased when combined with Dihydroergotamine.
DihydrostreptomycinMycophenolate mofetil may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DiltiazemThe metabolism of Mycophenolate mofetil can be decreased when combined with Diltiazem.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mycophenolate mofetil.
DipyridamoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dipyridamole.
DoxazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxepin.
DoxorubicinMycophenolate mofetil may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DoxorubicinThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Mycophenolate mofetil can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Mycophenolate mofetil can be decreased when combined with Dronedarone.
DrospirenoneMycophenolate mofetil may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Droxicam.
Edetic AcidMycophenolate mofetil may increase the anticoagulant activities of Edetic Acid.
EdoxabanMycophenolate mofetil may increase the anticoagulant activities of Edoxaban.
EfavirenzThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Elbasvir.
EltrombopagThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Eltrombopag.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Mycophenolate mofetil.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Mycophenolate mofetil.
EnoxaparinMycophenolate mofetil may increase the anticoagulant activities of Enoxaparin.
EnzalutamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Enzalutamide.
EpirizoleThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Epirizole.
EpirubicinMycophenolate mofetil may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneMycophenolate mofetil may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolate mofetil.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolate mofetil.
ErgonovineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Mycophenolate mofetil can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Eslicarbazepine acetate.
EsmololMycophenolate mofetil may decrease the antihypertensive activities of Esmolol.
EstramustineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Estrone.
Etacrynic acidMycophenolate mofetil may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Mycophenolate mofetil.
Ethyl biscoumacetateMycophenolate mofetil may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etofenamate.
EtoposideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Etoposide.
EtoricoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Etoricoxib.
EtravirineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with exisulind.
FelodipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Mycophenolate mofetil.
FentanylThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fidaxomicin.
FingolimodMycophenolate mofetil may increase the immunosuppressive activities of Fingolimod.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mycophenolate mofetil.
FluconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Fluconazole.
FlunixinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flunixin.
FluoxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Flurazepam.
FlurbiprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Flurbiprofen.
FluvoxamineThe metabolism of Mycophenolate mofetil can be decreased when combined with Fluvoxamine.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolate mofetil.
Fondaparinux sodiumMycophenolate mofetil may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolate mofetil.
FosamprenavirThe metabolism of Mycophenolate mofetil can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fosaprepitant.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Mycophenolate mofetil.
FosphenytoinThe metabolism of Mycophenolate mofetil can be increased when combined with Fosphenytoin.
FramycetinMycophenolate mofetil may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideMycophenolate mofetil may decrease the diuretic activities of Furosemide.
Fusidic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Fusidic Acid.
GefitinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Gefitinib.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mycophenolate mofetil.
GemfibrozilThe metabolism of Mycophenolate mofetil can be decreased when combined with Gemfibrozil.
GenisteinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Genistein.
GentamicinMycophenolate mofetil may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
GlyburideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Grepafloxacin.
HaloperidolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Haloperidol.
HaloperidolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Haloperidol.
HeparinMycophenolate mofetil may increase the anticoagulant activities of Heparin.
HirulogMycophenolate mofetil may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with HMPL-004.
HydralazineMycophenolate mofetil may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Mycophenolate mofetil.
HydrocortisoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Hydrocortisone.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolate mofetil.
Hygromycin BMycophenolate mofetil may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Icatibant.
IdarubicinMycophenolate mofetil may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Idelalisib.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolate mofetil.
ImatinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Imipramine.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolate mofetil.
IndenololMycophenolate mofetil may decrease the antihypertensive activities of Indenolol.
IndinavirThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Indinavir.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Mycophenolate mofetil.
IndoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolate mofetil.
IsavuconazoniumThe metabolism of Mycophenolate mofetil can be decreased when combined with Isavuconazonium.
IsoxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Isoxicam.
IsradipineThe metabolism of Mycophenolate mofetil can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ivermectin.
KanamycinMycophenolate mofetil may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Kebuzone.
KetamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ketoconazole.
KetoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Mycophenolate mofetil.
LabetalolMycophenolate mofetil may decrease the antihypertensive activities of Labetalol.
LansoprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Leflunomide.
LepirudinMycophenolate mofetil may increase the anticoagulant activities of Lepirudin.
LevobunololMycophenolate mofetil may decrease the antihypertensive activities of Levobunolol.
LevofloxacinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Liotrix.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Mycophenolate mofetil.
LithiumThe serum concentration of Lithium can be increased when it is combined with Mycophenolate mofetil.
LomitapideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Loratadine.
LornoxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Mycophenolate mofetil.
LovastatinThe metabolism of Mycophenolate mofetil can be decreased when combined with Lovastatin.
LoxoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolate mofetil.
LuliconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Lumacaftor.
LumiracoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Lumiracoxib.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Magnesium salicylate.
MaprotilineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Maprotiline.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolate mofetil.
MebendazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mebendazole.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mefenamic acid.
MefloquineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Megestrol acetate.
MeloxicamThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Meloxicam.
MeprobamateThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Meprobamate.
MesalazineMycophenolate mofetil may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Mycophenolate mofetil.
MetamizoleThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Metamizole.
MethadoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolate mofetil.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolate mofetil.
MetipranololMycophenolate mofetil may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolate mofetil.
MetoprololMycophenolate mofetil may decrease the antihypertensive activities of Metoprolol.
MetoprololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Metoprolol.
MetrizamideMycophenolate mofetil may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MibefradilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Midazolam.
MifepristoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Mifepristone.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolate mofetil.
MitomycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Mitoxantrone.
ModafinilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Modafinil.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Mycophenolate mofetil.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolate mofetil.
MorphineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Morphine.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Mycophenolate mofetil.
NadololMycophenolate mofetil may decrease the antihypertensive activities of Nadolol.
NadroparinMycophenolate mofetil may increase the anticoagulant activities of Nadroparin.
NafcillinThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Naftifine.
NaltrexoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Naltrexone.
NaproxenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Naproxen.
NaringeninThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.
NCX 4016The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with NCX 4016.
NefazodoneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nelfinavir.
NeomycinMycophenolate mofetil may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NeostigmineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Neostigmine.
NepafenacThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nepafenac.
NetilmicinMycophenolate mofetil may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
NetupitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Mycophenolate mofetil can be decreased when combined with Nevirapine.
NicardipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nicardipine.
NifedipineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Niflumic Acid.
NilotinibThe metabolism of Mycophenolate mofetil can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Nimesulide.
NisoldipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Norethisterone.
OlaparibThe metabolism of Mycophenolate mofetil can be decreased when combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolate mofetil.
OlopatadineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Olopatadine.
OlsalazineMycophenolate mofetil may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Mycophenolate mofetil.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Mycophenolate mofetil.
OmeprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Omeprazole.
OrgoteinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Orgotein.
OsimertinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Osimertinib.
OtamixabanMycophenolate mofetil may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxaprozin.
OxprenololMycophenolate mofetil may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Oxyphenbutazone.
P-NitrophenolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Palmitic Acid.
PamidronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pamidronate.
PantoprazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pantoprazole.
ParecoxibThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Parecoxib.
ParomomycinMycophenolate mofetil may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
ParoxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Paroxetine.
PenbutololMycophenolate mofetil may decrease the antihypertensive activities of Penbutolol.
PentobarbitalThe metabolism of Mycophenolate mofetil can be increased when combined with Pentobarbital.
Pentosan PolysulfateMycophenolate mofetil may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mycophenolate mofetil.
PhenindioneMycophenolate mofetil may increase the anticoagulant activities of Phenindione.
PhenobarbitalThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Phenobarbital.
PhenprocoumonMycophenolate mofetil may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Phenylbutazone.
PhenytoinThe metabolism of Mycophenolate mofetil can be increased when combined with Phenytoin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolate mofetil.
PimozideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pimozide.
PindololMycophenolate mofetil may decrease the antihypertensive activities of Pindolol.
PioglitazoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Pioglitazone.
PiretanideMycophenolate mofetil may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Mycophenolate mofetil.
Platelet Activating FactorThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Platelet Activating Factor.
PlicamycinMycophenolate mofetil may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolate mofetil.
PonatinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Posaconazole.
PractololMycophenolate mofetil may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mycophenolate mofetil.
PravastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Prednisone.
PrimidoneThe metabolism of Mycophenolate mofetil can be increased when combined with Primidone.
ProbenecidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Promethazine.
PropacetamolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Propacetamol.
PropafenoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propafenone.
PropranololMycophenolate mofetil may decrease the antihypertensive activities of Propranolol.
PropranololThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Mycophenolate mofetil.
Protein CMycophenolate mofetil may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeMycophenolate mofetil may increase the anticoagulant activities of Protocatechualdehyde.
ProtriptylineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Protriptyline.
PTC299The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with PTC299.
PuromycinMycophenolate mofetil may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuercetinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinacrine.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Mycophenolate mofetil.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolate mofetil.
QuinidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Rabeprazole.
Rabies vaccineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Rabies vaccine.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Mycophenolate mofetil.
RanitidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ranolazine.
ReboxetineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Regorafenib.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Mycophenolate mofetil.
ReserpineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Reserpine.
ResveratrolThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Resveratrol.
ReviparinMycophenolate mofetil may increase the anticoagulant activities of Reviparin.
RibostamycinMycophenolate mofetil may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RifabutinThe metabolism of Mycophenolate mofetil can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Mycophenolate mofetil can be increased when combined with Rifapentine.
RilpivirineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Rilpivirine.
RisedronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Risedronate.
RitonavirThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Ritonavir.
RivaroxabanMycophenolate mofetil may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Mycophenolate mofetil.
RoflumilastRoflumilast may increase the immunosuppressive activities of Mycophenolate mofetil.
RolapitantThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Rolapitant.
RosiglitazoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Rosiglitazone.
SalicylamideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salicylic acid.
SalsalateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Salsalate.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolate mofetil.
SaquinavirThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Saquinavir.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mycophenolate mofetil.
ScopolamineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Scopolamine.
SecobarbitalThe metabolism of Mycophenolate mofetil can be increased when combined with Secobarbital.
SelegilineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Selegiline.
SeratrodastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Seratrodast.
SertralineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Mycophenolate mofetil can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolate mofetil.
SirolimusThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Sirolimus.
SorafenibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sorafenib.
SotalolMycophenolate mofetil may decrease the antihypertensive activities of Sotalol.
SpectinomycinMycophenolate mofetil may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Mycophenolate mofetil.
SpironolactoneMycophenolate mofetil may decrease the antihypertensive activities of Spironolactone.
SpironolactoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with SRT501.
St. John's WortThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with St. John&#39;s Wort.
StaurosporineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Stiripentol.
StreptomycinMycophenolate mofetil may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinMycophenolate mofetil may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Streptozocin.
SulfamethoxazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Sulfamethoxazole.
SulfasalazineMycophenolate mofetil may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mycophenolate mofetil.
SulfinpyrazoneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Mycophenolate mofetil.
SulodexideMycophenolate mofetil may increase the anticoagulant activities of Sulodexide.
SumatriptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Sunitinib.
SuprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Suprofen.
TacrineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Mycophenolate mofetil.
TacrolimusMycophenolate mofetil may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mycophenolate mofetil.
TamoxifenThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tamoxifen.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolate mofetil.
Taurocholic AcidThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Taurocholic Acid.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Technetium Tc-99m Medronate.
TelaprevirThe metabolism of Mycophenolate mofetil can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Mycophenolate mofetil can be decreased when combined with Telithromycin.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolate mofetil.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Mycophenolate mofetil.
TemsirolimusThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Temsirolimus.
TenofovirThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Mycophenolate mofetil.
TepoxalinThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tepoxalin.
TerazosinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Teriflunomide.
TeriflunomideThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Teriflunomide.
TesmilifeneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Testosterone.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiaprofenic acid.
TicagrelorThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Mycophenolate mofetil can be decreased when combined with Ticlopidine.
TiludronateThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tiludronate.
TimololMycophenolate mofetil may decrease the antihypertensive activities of Timolol.
TobramycinMycophenolate mofetil may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TocilizumabThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Tocilizumab.
TofacitinibMycophenolate mofetil may increase the immunosuppressive activities of Tofacitinib.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Mycophenolate mofetil.
TolvaptanThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Tolvaptan.
TorasemideMycophenolate mofetil may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Mycophenolate mofetil.
TranilastThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Tranilast.
TrastuzumabTrastuzumab may increase the neutropenic activities of Mycophenolate mofetil.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolate mofetil.
TrazodoneThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trazodone.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolate mofetil.
TriamtereneMycophenolate mofetil may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolate mofetil.
TrifluoperazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Trimipramine.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trisalicylate-choline.
TroleandomycinThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Troleandomycin.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Mycophenolate mofetil.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolate mofetil.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Mycophenolate mofetil.
VenlafaxineThe metabolism of Mycophenolate mofetil can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Mycophenolate mofetil can be decreased when combined with Verapamil.
VinblastineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Vinorelbine.
VoriconazoleThe metabolism of Mycophenolate mofetil can be decreased when combined with Voriconazole.
WarfarinMycophenolate mofetil may increase the anticoagulant activities of Warfarin.
XimelagatranMycophenolate mofetil may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zileuton.
ZimelidineThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Mycophenolate mofetil can be decreased when combined with Ziprasidone.
Zoledronic acidThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Zomepirac.
Food Interactions
  • Do not take calcium, aluminium, magnesium or iron supplements within 2 hours of taking this medication.
  • Take on empty stomach: 1 hour before or 2 hours after meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH1
Uniprot ID:
P20839
Molecular Weight:
55405.365 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Bremer S, Rootwelt H, Bergan S: Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin Chem. 2007 Jun;53(6):1023-9. Epub 2007 Apr 26. [PubMed:17463174 ]
  4. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, Fu J, Shah T, Pravica V, Hutchinson IV, Burckart GJ: IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther. 2008 May;83(5):711-7. Epub 2007 Sep 12. [PubMed:17851563 ]
  5. Sanquer S, Maison P, Tomkiewicz C, Macquin-Mavier I, Legendre C, Barouki R, Lang P: Expression of inosine monophosphate dehydrogenase type I and type II after mycophenolate mofetil treatment: a 2-year follow-up in kidney transplantation. Clin Pharmacol Ther. 2008 Feb;83(2):328-35. Epub 2007 Aug 22. [PubMed:17713475 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna binding
Specific Function:
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. It may also have a role in t...
Gene Name:
IMPDH2
Uniprot ID:
P12268
Molecular Weight:
55804.495 Da
References
  1. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, Catalano G, De Simone P, Mosca F, Del Tacca M: An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004 Nov;36(9):2787-90. [PubMed:15621150 ]
  2. Bremer S, Rootwelt H, Bergan S: Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin Chem. 2007 Jun;53(6):1023-9. Epub 2007 Apr 26. [PubMed:17463174 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and diconjugate. Is also able to catalyze the glucuronidation of 17beta-estradiol, 17alpha-ethinylestradiol, 1-hydroxypyrene, 4-methylumbelliferone, 1-naph...
Gene Name:
UGT1A1
Uniprot ID:
P22309
Molecular Weight:
59590.91 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A7
Uniprot ID:
Q9HAW7
Molecular Weight:
59818.315 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein homodimerization activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks transferase activity but acts as a negative regulator of isoform 1 (By similarity).
Gene Name:
UGT1A6
Uniprot ID:
P19224
Molecular Weight:
60750.215 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A8
Uniprot ID:
Q9HAW9
Molecular Weight:
59741.035 Da
References
  1. Thervet E, Anglicheau D, Legendre C: [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7. [PubMed:11817210 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Protein kinase c binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A10
Uniprot ID:
Q9HAW8
Molecular Weight:
59809.075 Da
References
  1. Thervet E, Anglicheau D, Legendre C: [Pharmacology of mycophenolate mofetil: recent data and clinical consequences]. Nephrologie. 2001;22(7):331-7. [PubMed:11817210 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Triglyceride lipase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Hydrolyzes aromatic and aliphatic esters, but has no catalytic activity toward amides or a fatty acyl-CoA ester. Hydrolyzes the methyl ester group of cocaine to form benzoylecgonine. Catalyzes the transesterification of cocaine to form cocaethylene. Displays fatty acid ethyl ester synthase activity,...
Gene Name:
CES1
Uniprot ID:
P23141
Molecular Weight:
62520.62 Da
References
  1. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S: Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos. 2010 Dec;38(12):2210-7. doi: 10.1124/dmd.110.034249. Epub 2010 Sep 7. [PubMed:20823294 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Methylumbelliferyl-acetate deacetylase activity
Specific Function:
Involved in the detoxification of xenobiotics and in the activation of ester and amide prodrugs. Shows high catalytic efficiency for hydrolysis of cocaine, 4-methylumbelliferyl acetate, heroin and 6-monoacetylmorphine.
Gene Name:
CES2
Uniprot ID:
O00748
Molecular Weight:
61806.41 Da
References
  1. Fujiyama N, Miura M, Kato S, Sone T, Isobe M, Satoh S: Involvement of carboxylesterase 1 and 2 in the hydrolysis of mycophenolate mofetil. Drug Metab Dispos. 2010 Dec;38(12):2210-7. doi: 10.1124/dmd.110.034249. Epub 2010 Sep 7. [PubMed:20823294 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Picard N, Cresteil T, Premaud A, Marquet P: Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. Ther Drug Monit. 2004 Dec;26(6):600-8. [PubMed:15570183 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B1
Uniprot ID:
Q9Y6L6
Molecular Weight:
76447.99 Da
References
  1. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Michelon H, Konig J, Durrbach A, Quteineh L, Verstuyft C, Furlan V, Ferlicot S, Letierce A, Charpentier B, Fromm MF, Becquemont L: SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010 Dec;11(12):1703-13. doi: 10.2217/pgs.10.132. [PubMed:21142914 ]
  2. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Inoue T, Suzuki T, Habuchi T: Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9. Epub 2007 Sep 29. [PubMed:17906856 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T: Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64. doi: 10.1097/FTD.0b013e3181838063. [PubMed:18695635 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Miura M, Kagaya H, Satoh S, Inoue K, Saito M, Habuchi T, Suzuki T: Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. Ther Drug Monit. 2008 Oct;30(5):559-64. doi: 10.1097/FTD.0b013e3181838063. [PubMed:18695635 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23